Kaya (OTCMKTS:KAYS – Get Free Report) and Corcept Therapeutics (NASDAQ:CORT – Get Free Report) are both consumer discretionary companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.
Profitability
This table compares Kaya and Corcept Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kaya | N/A | -9.79% | -1,143.19% |
| Corcept Therapeutics | 22.35% | 24.54% | 20.24% |
Valuation and Earnings
This table compares Kaya and Corcept Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kaya | $200,000.00 | 3.82 | $1.61 million | ($0.08) | -0.43 |
| Corcept Therapeutics | $685.45 million | 11.62 | $106.14 million | $1.16 | 64.72 |
Corcept Therapeutics has higher revenue and earnings than Kaya. Kaya is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Kaya has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Kaya and Corcept Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kaya | 0 | 0 | 0 | 0 | 0.00 |
| Corcept Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
Corcept Therapeutics has a consensus price target of $138.25, suggesting a potential upside of 84.14%. Given Corcept Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Kaya.
Institutional and Insider Ownership
93.6% of Corcept Therapeutics shares are held by institutional investors. 23.5% of Kaya shares are held by insiders. Comparatively, 20.8% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Corcept Therapeutics beats Kaya on 12 of the 14 factors compared between the two stocks.
About Kaya
Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Receive News & Ratings for Kaya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaya and related companies with MarketBeat.com's FREE daily email newsletter.
